Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Income per Common Share

Income per Common Share

3 Months Ended

Feb. 28, 2021

Earnings Per Share [Abstract]

Income per Common Share

Note 6 – Income per Common Share

The following table sets forth the calculation of basic and diluted earnings per share:

	For the three months ended February 28, 2021		For the three months ended February 29, 2020
Numerator:
Net Income	$	693,590	$	686,966
Denominator:
Weighted-average shares outstanding-basic		7,570,913		7,541,113
Dilutive common shares issuable upon exercise of stock options		627,678		587,144
Weighted-average shares-diluted		8,198,591		8,128,257
Earnings (Loss) per share:
Basic	$	0.09	$	0.09
Diluted	$	0.08	$	0.08

For the three months ended February 28, 2021, the Company excluded the effect of 39,000 outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive. For the three months ended February 29, 2020, the Company excluded the effect of 232,737 outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.